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Abstract. – Rhabdomyolysis is a rare pre-
sentation of hypokalemia, although muscle
weakness is a well-known manifestation of hy-
pokalemia. Primary aldosteronism is character-
ized by hypertension, suppressed plasma renin
activity, increased aldosterone excretion and
hypokalemia with metabolic alkalosis. Rhab-
domyolysis is not common in primary aldos-
teronism.
We present here a 40-year-old woman pre-
senting with rhabdomyolysis accompanied by
severe hypokalemia as heralding symptom of
primary aldosteronism.
Key Words:
Hypokalemia, Rhabdomyolysis, Primary aldostero-
nism.
Introduction
Primary aldosteronism (PA) was initially con-
sidered a rare disease affecting 1% of hyperten-
sive patients. Studies published in the last years
revealed that PA is the most frequent cause of
secondary arterial hypertension1. The main caus-
es of PA included aldosterone producing adeno-
ma (APA), unilateral and bilateral adrenal cortex
hyperplasia (IHA), the familial types of the dis-
ease and aldosterone secreting adrenal
carcinoma2,3. APA and unilateral adrenal hyper-
plasia (UAH) are treated by adrenalectomy,
whereas IHA is treated with aldosterone receptor
antagonists4.
Patients with PA typically present hyperten-
sion, and the uncontrolled synthesis of aldos-
terone leads to increased sodium reabsorption,
kaliuresis, varying degrees of hypokalemia and
metabolic alkalosis. The hypokalemia is usually
mild5. Nevertheless it could become extremely
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severe and even life threatening. In particular se-
rious complication of hypokalemia is the rhab-
domyolysis6 which may be the first manifestation
of the PA. At today few cases have been reported
in the English literature7-26.
Here, we present a new case of PA presenting
with rhabdomyolysis due to severe hypokalemia.
Case Report
A 40-year-old woman was referred to our Hos-
pital with severe myalgia involving legs, stiffness
and muscle weakness of the upper arms, lasting 4
days. She had a previous history of arterial hy-
pertension diagnosed two years previously and
treated with irbesartan plus hydrochlorothiazide.
The family history was negative for PA and his-
tory of hypokalemic disorder. She did not take
liquorice and herbs.
At the Emergency Department, laboratory
findings showed severe hypokalemia (K+ 1.64
mEq/L; normal range 3.4-5.5 mEq/L), metabol-
ic alkalosis (pH 7.58, pCO2 54 mmHg, HCO3-
44.3 mmol/L), increase of creatine phosphoki-
nase (CPK) 12.085 U/L (normal range 90-140
U/L) and myoglobinemia 1714 ng/ml (normal
range: 25-58 ng/ml). Based on these data and
clinical picture hypokalemic rhabdomyolysis
was diagnosed. Fluid intravenous (IV) hydration
and IV potassium supplementation were admin-
istered, and the patient was referred to Depart-
ment of Clinical Medicine, Nephrology and
Dialysis. At admission, her physical examina-
tion was unremarkable, apart from extreme
muscular weakness, especially of the arms and
the legs, rendering elevation above the shoulder
level almost impossible. No edema or rash was
detected. Blood pressure was 130/80 mmHg.
Electrocardiogram revealed flattered T waves
and prolongation of QT interval (QTc 597
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the serum CPK level (9122 U/L), high serum
myoglobin level (911 ng/ml) and metabolic alka-
losis (Table I). The patient was treated with IV
administration of potassium rich solutions fol-
lowed by reduction of hypokalemia and reversal
msec). The chest x-ray was normal, and 2-di-
mensional Doppler echocardiogram revealed a
mitral prolapse.
Laboratory findings confirmed severe hy-
pokalemia (1.66 mEq/L), extreme elevation of
At admission 3 weeks during 6 months after
Variables recovery At discharge recovery
Blood chemistry
WBC (× 103/µL) 6.4 6.5 4.98 4.72
RBC (× 103/µL) 441 420 413 428
HB (g/dL) 12.7 12.1 11.9 12.1
HCT (%) 36 34.4 33.6 39
PLT (× 103/µL) 26.3 25.2 19.6 22.1
BUN (mg/dL) 8 7 6.3 6.4
CREAT (mg/dL) 0.6 0.5 0.9 0.8
GOT (IU/L) 262 178 25 30
GPT (IU/L) 118 114 49 50
LDH (IU/L) 445 426 204 200
γGT (IU/L) 39 30 25 24
T-BIL (mg/dL) 0.48 0.46 0.52 0.48
Na (mEq/L) 142 141 138 139
K (mEq/L) 1.66 2.76 4.2 4.1
Cl (mEq/L) 90 101 102 103
Ca (mg/dL) 9.2 8.5 9.3 9.8
P (mg/dL) 2.3 2.9 3.1 3.5
Glucose (mg/dL) 84 81 74 85
T-chol (mg/dL) 128 - 158 168
TG (mg/dL) 117 - 127 81
HDL-C (mg/dL) 48 - 51 65
CPK (U/L) 9122 5273 124 77
CPK-MB (U/L) 16 10 4.1 0.8
Myoglobin (ng/ml) 911 631 55 14.6
Alb (g/dl) 4 4.2 4.1 4.2
Uric Acid (mg/dL) 1.6 1.8 1.7 2.5
Arterial blood gas analysis
pH 7.58 7.48 7.42 7.4
pO2 (mmHg) 61 69 88 92
pCO2 (mmHg) 52 47 33 32
HCO3- (mmHg) 48.8 35 21.4 20.4
B.E. (mmHg) 23.7 10.1 2.4 1.1
Urine excretion
Ca+ (mg/24h) 242 238 201 ––
P+ (mg/24h) 837 821 805 ––
K+ (mEq/24h) 88 53 35 ––
Cl– (mg/24h) 161 158 140 ––
Na+ (mEq/24h) 190 147 130 ––
Mg+ (mg/24h) 141 138 132 ––
Table I. Laboratory data at admission and follow-up.
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Follow up with Normal
Hormones At diagnosis eplerenone treatment range
Plasma renin activity (PRA) (ng/ml/h) 0.2 0.2 (0.3-2.7)
Plasma aldosterone (PAC) (ng/dl) 28.67 58.8 (3-16)
Plasma cortisol (PC) (µl/dl) 524.9 628.6 (266-720)
Plasma ACTH (pg/ml) 58.8 48.3 (10-90)
PAC/PRA ratio (ng/dl:ng/ml/h) 143 294 (< 30)
Urinary excretion
Urinary free cortisol (UFC) (nmol/24 h) 233.5 185.9 (38-208)
Urinary aldosterone (UA) (µg/24 h) 39.8 55.2 (2,84-34)
of muscular weakness (Table I). The combination
of hypokalemia, hyperkaluria, metabolic alkalo-
sis with hypertension raised the suspicion of in-
appropriate secretion of mineralcorticoids, and,
we performed hormonal analysis.
Plasma renin activity (PRA) was suppressed
(0.20 ng/ml/h) with an increase of plasma
(PAC) and urine aldosterone (UA) concentra-
tions (28.67 ng/dl and 39.8 ng/24h, respective-
ly), with a high PAC/PRA ratio (143
ng/dl:ng/ml/h) (Table II).
Suspecting an APA, we conducted further
evaluation. Abdominal magnetic resonance
(MR) showed multiple nodules in the bilateral-
ly adrenal glands (Figure 1A). Subsequently,
adrenal venous sampling (AVS) was performed
(Figure 1B). Proper placement of the catheter
tip was confirmed using a small amount of
contrast medium. The PAC levels in the left
and the right adrenal veins were 87.35 ng/dl
and 100.62 ng/dl, respectively. Based on the
plasma cortisol (PC) levels in the left and the
right adrenal veins (554 mmol/l and 577.8
nmol/l, respectively), we consider that the
catheters had been correctly inserted into the
adrenal vein.
All these results suggest no lateralization of
PAC from the adrenal glands and excluding the
possibility of surgical procedure in this case. The
patient was treated with an anti-aldosterone re-
ceptors drugs (spironolactone) and oral potassi-
um supplement with restoration of electrolytes
balance and good control of blood pressure
(130/80 mmHg) (Table I).
Six months after discharge the patient was
asymptomatic, and followed in our Specialized
Figure 1. Abdominal magnetic resonance scan (A) showed a bilateral adrenal nodules; (B) selective catheterism of adrenal
veins for adrenal venous sampling (AVS).
A B
Table II. Endocrine tests results.
Center of Secondary Hypertension. Physical ex-
amination was normal, her average blood pres-
sure was 130/85 mmHg, and 24-h-ambulatory
blood pressure monitoring (ABPM) showed
mean normal values (125/80 mmHg) with dip-
ping-profile. Electrocardiogram was normal.
General laboratory test did not reveal any re-
markable abnormalities, with normalization of
potassium, CPK and myoglobinemia values
(Table I). The patient continued receiving treat-
ment with an anti-aldosterone receptors drug
(eplerenone).
Discussion
Rhabdomyolysis is the destruction of a signifi-
cant amount of striated muscle, leading to disrup-
tions in fluid balance, electrolytes and renal func-
tion. Diagnosis is typically made though the
timely determination of the serum CPK in a pa-
tient with a suggestive history or clinical
features27,28. The most frequent symptoms of
rhabdomyolysis are fatigue, weakness, muscular
pain and swelling, although it is possible that
some patients are completely asymptomatic29.
The common and well known causes of rhab-
domyolysis include excessive physical exertion
trauma, alcoholism, drugs (such as statins),
liquorice, certain genetic disorders and elec-
trolytes disorders such as hypokalemia.
The presented patient showed severe hy-
pokalemia of 1.6 mEq/l associated with gener-
alized weakness and rhabdomyolysis. Severe
hypokalemia was attributed to PA due to bilat-
eral nodular adrenal glands. At today few com-
plete cases have been reported of PA excess be-
ing related to hypokalemic rhabdomyolysis in
the English literature7-26 (Table III).
The severity of neuromuscular disorders, in
the rhabdomyolysis, tends to be proportionate
to the rate at which hypokalemia develops.
Muscle destruction due to rhabdomyolysis
causes the release of large amounts of potassi-
um in the circulation. Consequently, where the
clinical syndrome of hypokalemia and rhab-
domyolysis develops, the absolute concentra-
tion of potassium is for below the normal lim-
its. Large amounts of potassium supplementa-
tion are necessary associated with generous in-
travenous hydratation29. Frank rhabdomyolysis
usually occurs only when serum potassium val-
ues are below 2.0 mEq/L30.
PA is characterized by the autonomous over-
production of aldosterone by the adrenal glands,
and only a minority of patients (less than one
half) presented with hypokalemia; the majority
of patients showing normokalemic hypertension,
especially in IHA1,31.
Potassium is predominantly an intracellular
cation, as only 2% of the total body potassium
can be found the extracellular space. The homeo-
static serum potassium concentration is main-
tained by the terminal nephron segments of the
kidney. Insulin, β-adrenergic agonists, aldos-
terone and a change is blood pH may all inde-
pendently affect the serum potassium levels32.
Severe hypokalemia might play an important
role in muscle damage, secondary to: (1) contrac-
tion of capillaries with reduction muscle blood
supply and resulting in lysing muscle cells; (2)
suppression of synthesis and storage of glycogen,
and (3) deranged ion transport across the cell
membrane33,34.
Conclusions
We report an unusual case of PA due to mul-
tiple bilateral nodules, presenting with rhab-
domyolysis secondary to severe hypokalemia
and not associated with the devolpment of
acute kidney injury. The prompt volume expan-
sion and correction of hypokalemia resolved
the rhabdomyolysis. It is possible that metabol-
ic alkalosis associated to hypokalemia may
have contribute to the good outcome of kidney
function.
This case underline the risk of hypokalemia-
induced rhabdomyolysis in patients with PA, in
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